Evaluation of a group a streptococcus synthetic oligosaccharide as vaccine candidate

Vaccine

Volumn 29, Issue 1, 2010, Pages 104-114

  Kabanova, Anna ^a,b,f   Margarit, Immaculada ^a   Berti, Francesco ^a   Romano, Maria R ^a   Grandi, Guido ^a   Bensi, Giuliano ^a   Chiarot, Emiliano ^a   Proietti, Daniela ^a   Swennen, Erwin ^a   Cappelletti, Emilia ^a   Fontani, Paola ^a   Casini, Daniele ^a   Adamo, Roberto ^a   Pinto, Vittoria ^a   Skibinski, David ^a   Capo, Sabrina ^a,g   Buffi, Giada ^a   Gallotta, Marilena ^a   Christ, William J ^c   Stewart Campbell, A ^c   Pena, John ^c   Seeberger, Peter H ^d,e   Rappuoli, Rino ^a   Costantino, Paolo ^a   more..

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Ancora Pharmaceuticals   (United States)

^d MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES   (Germany)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

^f Fondazione per l'istituto di ricerca in biomedicina   (Switzerland)

^g Presidio Ospedaliero Alta Val d'Elsa USL 7   (Italy)

Author keywords

Glycoconjugate vaccine; Group A Streptococcus

Indexed keywords

ANTISERUM; BACTERIUM ANTIBODY; BETA HEMOLYTIC STREPTOCOCCUS GROUP A POLYSACCHARIDE; GLYCOCONJUGATE; M PROTEIN; POLYSACCHARIDE VACCINE; RECOMBINANT VACCINE; STREPTOCOCCUS GROUP A OLIGOSACCHARIDE; STREPTOCOCCUS GROUP A POLYSACCHARIDE DIPHTHERIA TOXOID CRM197; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PURIFICATION; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; FEMALE; GROUP A STREPTOCOCCAL INFECTION; IMMUNITY; IMMUNOGENICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; STREPTOCOCCUS GROUP A;

ANIMALS; FEMALE; MICE; OLIGOSACCHARIDES; PHAGOCYTOSIS; RABBITS; SERUM; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 78649698736     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.018     Document Type: Article

References (60)

1. Mitchell T.J. The pathogenesis of streptococcal infections: from tooth decay to meningitis. Nature Reviews 2003, 1:219-230.
2. WHO programme for the prevention of rheumatic fever/rheumatic heart disease in 16 developing countries: report from Phase I (1986-90). WHO Cardiovascular Diseases Unit and principal investigators. Bulletin of the World Health Organization 1992;70:213-18.
3. Pitner J.B., Beyer W.F., Venetta T.M., Nycz C., Mitchell M.J., Harris S.L., et al. Bivalency and epitope specificity of a high-affinity IgG3 monoclonal antibody to the Streptococcus group A carbohydrate antigen. Molecular modeling of a Fv fragment. Carbohydrate Research 2000, 324:17-29.
4. Johnson M.A., Pinto B.M. Saturation transfer difference 1D-TOCSY experiments to map the topography of oligosaccharides recognized by a monoclonal antibody directed against the cell-wall polysaccharide of group A Streptococcus. Journal of the American Chemical Society 2002, 124:15368-15374.
5. Braun D.G. The use of streptococcal antigens to probe the mechanisms of immunity. Microbiology and Immunology 1983, 27:823-836.
6. Cunningham M.W. Pathogenesis of group A streptococcal infections. Clinical Microbiology Reviews 2000, 13:470-511.
7. Lancefield R.C. A serological differentiation of human and other groups of hemolytic Streptococci. The Journal of Experimental Medicine 1933, 57:571-595.
8. Mc C.M., Lancefield R.C. Variation in the group-specific carbohydrate of group A Streptococci. I. Immunochemical studies on the carbohydrates of variant strains. The Journal of Experimental Medicine 1955, 102:11-28.
9. Sabharwal H., Michon F., Nelson D., Dong W., Fuchs K., Manjarrez R.C., et al. Group A Streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. The Journal of Infectious Diseases 2006, 193:129-135.
10. Salvadori L.G., Blake M.S., McCarty M., Tai J.Y., Zabriskie J.B. Group A Streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. The Journal of Infectious Diseases 1995, 171:593-600.
11. Michon F., Moore S.L., Kim J., Blake M.S., Auzanneau F.I., Johnston B.D., et al. Doubly branched hexasaccharide epitope on the cell wall polysaccharide of group A Streptococci recognized by human and rabbit antisera. Infection and Immunity 2005, 73:6383-6389.
12. Stollerman G.H., Dale J.B. The importance of the Group A Streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clinical Infectious Diseases 2008, 46:1038-1045.
13. Shaila M.S., Nayak R., Prakash S.S., Georgousakis M., Brandt E., McMillan D.J., et al. Comparative in silico analysis of two vaccine candidates for group A Streptococcus predicts that they both may have similar safety profiles. Vaccine 2007, 25:3567-3573.
14. Jones K.F., Whitehead S.S., Cunningham M.W., Fischetti V.A. Reactivity of rheumatic fever and scarlet fever patients' sera with group A streptococcal M protein, cardiac myosin, and cardiac tropomyosin: a retrospective study. Infection and Immunity 2000, 68:7132-7136.
15. Plante O.J., Palmacci E.R., Seeberger P.H. Automated solid-phase synthesis of oligosaccharides. Science 2001, 291:1523-1527.
16. Reimer K.B., Gidney M.A., Bundle D.R., Pinto B.M. Immunochemical characterization of polyclonal and monoclonal Streptococcus group A antibodies by chemically defined glycoconjugates and synthetic oligosaccharides. Carbohydrate Research 1992, 232:131-142.
17. Safari D., Dekker H.A., Joosten J.A., Michalik D., de Souza A.C., Adamo R., et al. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14. Infection and Immunity 2008, 76:4615-4623.
18. Pozsgay V., Kubler-Kielb J., Schneerson R., Robbins J.B. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:14478-14482.
19. Habeeb A.F.S.A. Determination of free amino group in proteins by trinitrobenzensulfonic acid. Analytical Biochemistry 1966, 14:328-338.
20. Scott R.W., Moore W.E., Effland M.J., Millett M.A. Ultraviolet spectrophotometric determination of hexoses, pentoses, and uronic acids after their reactions with concentrated sulfuric acid. Analytical Biochemistry 1967, 21:68-80.
21. Haque K.A., Pfeiffer R.M., Beerman M.B., Struewing J.P., Chanock S.J., Bergen A.W. Performance of high-throughput DNA quantification methods. BMC Biotechnology 2003, 3:20.
22. Kwinn L.A., Khosravi A., Aziz R.K., Timmer A.M., Doran K.S., Kotb M., et al. Genetic characterization and virulence role of the RALP3/LSA locus upstream of the streptolysin S operon in invasive M1T1 Group A Streptococcus. Journal of Bacteriology 2007, 189:1322-1329.
23. Tanford C. Physical chemistry of macromolecules 1961, Wiley, New York.
24. Miron T., Wilchek M. A spectrophotometric assay for soluble and immobilized N-hydroxysuccinimide esters. Analytical Biochemistry 1982, 126:433-435.
25. Jennings H.J., Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. Journal of Immunology 1981, 127:1011-1018.
26. McCloskey N, Turner M.W., Goldblatt T.D. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). Journal of Immunological Methods 1997, 205:67-72.
27. Iversen T., Josephson S., Bundle D.R. The synthesis of streptococcal groups A, C and variant-a antigenic determinants. Perkin Transactions 1981, 1:2379-2385.
28. Waffenschmidt S., Jaenicke L. Assay of reducing sugars in the nanomole range with 2,2'-bicinchoninate. Analytical Biochemistry 1987, 165:337-340.
29. Franco-Fraguas L., Pla A., Ferreira F., Massaldi H., Suarez N., Batista-Viera F. Preparative purification of soybean agglutinin by affinity chromatography and its immobilization for polysaccharide isolation. Journal of Chromatography 2003, 790:365-372.
30. Giannini G., Rappuoli R., Ratti G. The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Research 1984, 12:4063-4069.
31. Bröker M., Dull P.M., Rappuoli R., Costantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine 2009, 27:5574-5580.
32. Jackson L.A., Jacobson R.M., Reisinger K.S., Anemona A., Danzig L.E., Dull P.M. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. The Pediatric Infectious Disease Journal 2009, 28:86-91.
33. Stewart-Tull D.E. Adjuvant formulations for experimental vaccines. Methods in Molecular Medicine 2003, 87:175-194.
34. Bloom B.R., Lambert P.H. The vaccine book 2003, Academic Press, Elsevier, San Diego, CA, p. 65.
35. Wessels M.R., Moses A.E., Goldberg J.B., DiCesare T.J. Hyaluronic acid capsule is a virulence factor for mucoid group A Streptococci. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:8317-8321.
36. Wessels M.R., Goldberg J.B., Moses A.E., DiCesare T.J. Effects on virulence of mutations in a locus essential for hyaluronic acid capsule expression in group A Streptococci. Infection and Immunity 1994, 62:433-441.
37. Schmidt W.C., Moore D.J. The determination of antibody to group a Streptococcal polysaccharide in human sera by hemagglutination. The Journal of Experimental Medicine 1965, 121:793-806.
38. Karakawa W.W., Osterland C.K., Krause R. Detection of Streptococcal group-specific antibodies in human sera. The Journal of Experimental Medicine 1965, 122:195-205.
39. Zimmerman R.A., Auernheimer A.H., Taranta A. Precipitating antibody to group A streptococcal polysaccharide in humans. Journal of Immunology 1971, 107:832-841.
40. Paul J.R. The epidemiology of rheumatic fever 1957, American Heart Association, New York, 19-21.
41. Shikhman A.R., Greenspan N.S., Cunningham M.W. A subset of mouse monoclonal antibodies cross-reactive with cytoskeletal proteins and group A streptococcal M proteins recognizes N-acetyl-beta-d-glucosamine. Journal of Immunology 1993, 151:3902-3913.
42. Malkiel S., Liao L., Cunningham M.W., Diamond B. T-Cell-dependent antibody response to the dominant epitope of streptococcal polysaccharide, N-acetyl-glucosamine, is cross-reactive with cardiac myosin. Infection and Immunity 2000, 68:5803-5808.
43. Kirvan C.A., Swedo S.E., Snider L.A., Cunningham M.W. Antibody-mediated neuronal cell signaling in behavior and movement disorders. Journal of Neuroimmunology 2006, 179:173-179.
44. Kalinski P., Moser M. Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses. Nature Reviews Immunology 2005, 5:251-260.
45. Pozsgay V., Chu C., Pannell L., Wolfe J., Robbins J.B., Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:5194-5197.
46. Stanley J., Linton D., Desai M., Efstratiou A., George R. Molecular subtyping of prevalent M serotypes of Streptococcus pyogenes causing invasive disease. Journal of Clinical Microbiology 1995, 33:2850-2855.
47. Benaissa-Trouw B., Lefeber D.J., Kamerling J.P., Vliegenthart J.F., Kraaijeveld K., Snippe H. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Infection and Immunity 2001, 69:4698-4701.
48. Jansen W.T., Hogenboom S., Thijssen M.J., Kamerling J.P., Vliegenthart J.F., Verhoef J., et al. Synthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in mice. Infection and Immunity 2001, 69:787-793.
49. Verez-Bencomo V., Fernandez-Santana V., Hardy E., Toledo M.E., Rodriguez M.C., Heynngnezz L., et al. A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 2004, 305:522-525.
50. Chong P., Chan N., Kandil A., Tripet B., James O., Yang Y.P., et al. A strategy for rational design of fully synthetic glycopeptide conjugate vaccines. Infection and Immunity 1997, 65:4918-4925.
51. Robbins J.B., Kubler-Kielb J., Vinogradov E., Mocca C., Pozsgay V., Shiloach J., et al. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:7974-7978.
52. Saksena R., Adamo R., Kovac P. Immunogens related to the synthetic tetrasaccharide side chain of the Bacillus anthracis exosporium. Bioorganic & Medicinal Chemistry 2007, 15:4283-4310.
53. Kamena F., Tamborrini M., Liu X., Kwon Y.U., Thompson F., Pluschke G., et al. Synthetic GPI array to study antitoxic malaria response. Nature Chemical Biology 2008, 4:238-240.
54. Schofield L., Hewitt M.C., Evans K., Siomos M.A., Seeberger P.H. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002, 418:785-789.
55. Liu X., Siegrist S., Amacker M., Zurbriggen R., Pluschke G., Seeberger P.H. Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chemical Biology 2006, 1:161-164.
56. Ratner D.M., Adams E.W., Disney M.D., Seeberger P.H. Tools for glycomics: mapping interactions of carbohydrates in biological systems. ChemBioChem 2004, 5:1375-1383.
57. Ragupathi G., Koide F., Livingston P.O., Cho Y.S., Endo A., Wan Q., et al. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. Journal of the American Chemical Society 2006, 128:2715-2725.
58. Wang D., Carroll G.T., Turro N.J., Koberstein J.T., Kovac P., Saksena R., et al. Photogenerated glycan arrays identify immunogenic sugar moieties of Bacillus anthracis exosporium. Proteomics 2007, 7:180-184.
59. Liakatos A., Kunz H. Synthetic glycopeptides for the development of cancer vaccines. Current Opinion in Molecular Therapeutics 2007, 9:35-44.
60. Galonic D.P., Gin D.Y. Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines. Nature 2007, 446:1000-1007.